Protocol Deviations: Summary and Trends

MTN Annual Meeting MTN-017 Protocol Team Meeting February 10, 2013



Introduction

- Review of PD reporting process
- Summary of Common PDs
- Trends
- Questions



PD Reporting Process

- Identify the PD
 - Prospectively
 - > Retrospectively
 - > Prior to occurrence
- Document the PD
 - Site staff
 - No stipulation on who must document it, as long as it is recorded in the participant's study record
 - What works best at the site
- Report the PD
 - Complete PD CRF Log



Reporting

	Tricipant ID Completion Date dd MMM yy Otocol Deviation Log
1.	Site awareness date: dd MMM yy
2.	Deviation date:
3.	yes no Has or will this deviation be reported to local IRB/EC?
4.	Has or will this deviation be reported to DAIDS as a
5.	Type of deviation: deviation code (See back of form for code listing.)
6.	Description of deviation:
7.	Plans and/or action taken to address the deviation:
3.	Plans and/or action taken to prevent future occurrences of the deviation:
).	Deviation reported by: staff code

	Purpose:	This form documents and reports protocol	deviatio	ns identified for study participants.
G	Instructions:			is identified. Consult the MTN Regulatory Team lanagement Team if you are unsure if an event requires repor
em-spc	cific Instructions:			
		Number pages sequentially for each partic for deletion.	cipant, str	arting with 01. Do not re-assign page numbers if a form is ma
	Item 2:	Record the date the event occurred (start	date).	
		Record the two-digit calegory code that be categories match. Describe the specifics of		ibes the type of deviation. Use "99" (other) if none of the liste diation in Hem 6.
Code	Description		Code	Description
01	Inappropriate enrollment: The participant enrolled and not all elgibility requirements were met. Failure to follow trial randomization or blinding procedures: Include instances where randomization procedures were not followed by site staff, or product blinding procedures were not followed by pharmacy staff.		12	Breach of confidentiality: Include potential and actual cases where participant confidentiality is breached. For example, a staff member puts a participant's name on a creport form.
02				
			13	Physical assessment deviation; include missed or incomplete physical/pelvic/rectal exam assessments.
03	Study product management deviation: The site staff did not instruct the participant to hold, permanently discontinue,			Lab assessment deviation: Include missed, or incomplet lab specimen collection.
04	or resume study product use per protocol requirements. Study product dispensing error: The wrong study product was dispensed to a participant, or study product was			Mishandled lab specimen: Include errors in the labeling, physical handling, processing, testing, storage, or shipmer of collected lab specimens.
05	dispensed to a participant on product hold. Do not include any information related to study product assignment (product codes) on this form. Pharmacy staff must follow up with the MTN Pharmacist separately. Study product use/non-use deviation: Participant did not		16	Staff performing duties that they are not qualified to perform: Use for any instance when any study procedure, including clinical and administrative procedures, is complet by a staff member who is not adequately qualified AND delegated to perform the procedure.
	use the study product (including product refusels) or used it incorrectly (i.e., not in accordance with protocol requirements).			Questionnaire administration deviation: A required questionnaire was not completed according to protocol requirements. Include instances where the wrong
06	Study product sharing: Participant has shared study product with another person or study participant.		18	questionnaire was completed. Counseling deviation: Protocol-required counseling was
07 Study product not returned by the carticipant of		eturned: Study product was not cipant per protocol requirements.	-	not done and/or not documented correctly.
80	Conduct of non-protocol procedure: A clinical or administrative procedure was performed that was not specified in the protocol, and was not covered under local standard of care practice.		19	Use of non-IRB/EC-approved materials: Include use of ANY study-related material that requires IRB or EC approv for use per site requirements.
			20	Use of excluded concomitant medications, devices or non-study products
09	Improper AE/EAE follow-up: Use when an AE or EAE is not followed per protocol. For example, a clinical finding/lab result is not re-assessed as cutfined in the protocol.		21	Informed consent process deviation: Examples include failure to accurately execute and/or document any part of the informed consent process.
10	Unreported AE: Site staff become aware of an AE, but do not report it per protocol requirements.		22	Visit completed outside of window: Use when visit procedures for a visit are done within the wrong window or not in a designated visit window. For example, use if Visit 3 procedures are done in the Visit 4.0 window.
11	Unreported EAE: Site staff become aware of an EAE, but do not report it per protocol and DAIDS EAE Manual requirements.			
			99	Other

each site staff person who will be completing this form. This list is created, maintained, and kept at the study site.

Version 1.0, 14-NOV-12

NthiwellomsWTN_020/ornsin020_PDL.fm





English Staff Initials / Date




Common PDs by Category





- Three most commonly reported PDs
 - 1. Mishandled Laboratory Sample Deviation 42%
 - 2. Study Product Use/Non Use Deviation 21%
 - 3. Physical Assessment Deviation 11%
- Constitute 75% of all reported PDs
- 2 PDs (~ .5%)have been reported to DAIDS as potential Critical Events thus far







- FDA's "Most Commonly Cited PD's*" are:
 - Inappropriate enrollment (participant failed to meet eligibility criteria)
 - Physical assessment deviation (incomplete, incorrect, and/or missed assessment)
 - Laboratory evaluation deviation (incomplete, incorrect, missed evaluation and/or review of laboratory results/reports)
 - > Study product non-adherence



^{*} FDA site inspections occurring during 2008 and early 2009

Laboratory evaluation deviation

 Mishandled Laboratory Sample Deviation (42%)

Study product non-adherence


 Study Product Use/Non Use Deviation (21%)

Physical assessment deviation

 Physical Assessment Deviation (11%)



Breakdown of "Other" PDs





Questions & Discussion





Thank you!

